Tools and Guidelines

Project Inform and Outshine NW partnered to write this PrEP resource guide for women who are transgender and for other trans/gender-variant people who were assigned male sex at birth.  By the end of this book, you will: 1. know how to find more information about PrEP; 2. know how to find an accessible healthcare provider; 3. know how to to ask for PrEP; 4. know where to get support to advocate for yourself if you run into any hurdles along the way; and 5. have a better idea whether PrEP is an HIV prevention tool you want to use.

The objectives of these updated WHO Guidelines are to provide evidence-based recommendations for the treatment of persons with hepatitis C infection using, where possible, all-oral combinations of these new medicines, also called direct-acting antivirals (DAAs). The Guidelines also provide recommendations on the preferred regimens based on a patient’s HCV genotype and clinical history, and assess the appropriateness of continued use of the existing medicines. The key audience for these guidelines are policy-makers in low- and middle-income countries who formulate country-specific treatment guidelines, and who plan infectious disease treatment programmes and services, in addition to those people responsible for delivering treatment. The Guidelines are appropriate for all countries, including high-income countries.

The purpose of this document is to provide guidance to national AIDS programmes and partners on the use of core indicators to measure and report on the country response. These guidelines are designed to improve the quality and consistency of data collected at the country level, enhancing the accuracy of conclusions drawn at national, regional and global levels.

This manual addresses the early phase of implementation of GLASS, focussing on surveillance of resistance in common human bacterial pathogens. The intended readership of this publication is public health professionals and health authorities responsible for national AMR surveillance. It outlines the GLASS standards and describes the road map for implementation of the system between 2015 and 2019. Further development of GLASS will be based on the lessons learnt during this period.

Developed by Southern African AIDS Trust, with the support of WHO and UNAIDS, the summary of the the WHO’s New Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection is now available. Among many new recommendations is that antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Another is that the use of daily oral pre-exposure prophylaxis (PrEP) is recommended as a prevention choice for people at substantial risk of HIV infection as part of combination prevention approaches.

Tuberculosis continues to be a public health challenge in India and it is commonest opportunistic infection in persons living with HIV (PLHIV), TB is the foremost cause of dath among people living with HIV. To mitigate the effect of dual burden of HIV and TB co-infection the ministry of Health and Family Welfare, Government of India through its National AIDS Control Organisation (NACO) and Central TB Division has been undertaking joint collaborative efforts as per the National Framework for HIV TB collaborative activities in India. Training of staff under NACP and RNTCP is very crucial for strengthening of TB/HIV activities and imparting updated knowledge regarding HIV/TB to program staff. To streamline the training, both  the programmes envisage, that uniform, standardized modular training be imparted to all the programme and general health staff throughout the country.

As described in the Framework for engagement of all health-care providers in the management of drug-resistant tuberculosis, a careful country-based analysis about the current status of the management of drug-resistant tuberculosis (DR-TB) patients, with a focus on all the various health-care providers, will show the way forward towards achieving the goal of universal access to quality diagnosis and treatment for all cases of TB, including DR-TB. This situation assessment tool, as an annex of the above-mentioned framework, enables a country or other users to gather the needed data that will serve as a basis for designing a sound plan of expanding DR-TB management, by engaging all relevant care providers.

The 2015 revision of a guide to monitoring and evaluation for collaborative TB/HIV activities is developed through close collaboration between the World Health Organization, the United States President’s Emergency Plan for AIDS Relief, the Joint United Nations Programme on HIV and AIDS and the Global Fund to Fight AIDS, Tuberculosis and Malaria and extensive consultations with partners and national programmes. It renews focus on quality of data and its utility for programmatic response. The monitoring indicators are broadly categorized into core indicators for global and national level use and optional indicators. While the core indicators enable monitoring of key TB/HIV interventions as in the past, some are modified to enhance accuracy of data and others to broaden scope. This guide is developed to assist TB and HIV programme managers and other stakeholders in monitoring and evaluation for collaborative TB/HIV activities. It is intended to facilitate collection of standardized data and to help in interpretation and dissemination of these data for programme improvement at national and subnational level.

The Ministry of Public Health (MoPH) of the Islamic Republic of Afghanistan is very pleased to present this newly revised Second Version of the Prison Health Services Strategy (PHSS) 2015/1394. Prisoners and juveniles are part of general community of Afghanistan. Based on the laws they are kept for a specific period of time in detention places. All rights of the prisoners and juveniles detainees are in place. Because of that the MoPH created prison health department according to its policies and strategies. The MoPH developed PHS strategy and package in order to provide health services to this vulnerable group of people. This revision is based on the increased in the number of prisoners, prisoners’ health needs, and lessons learnt from the implementation of the first version of the Prison Health Services (PHS) Strategy.

This HIV clinical management guideline is substantially changed from the 2012 guidelines. This is a consolidated guideline, including sections on antiretroviral therapy and opportunistic infections, which were previously contained in two separate documents. In addition to avoiding repetition, the intention is also to make the format more concise, with more dot points, tables and algorithms than paragraphed text. The changing clinical needs of PLHIV necessitate a broadening of the scope of the guideline. As more PLHIV are now established on combination antiretroviral therapy they will experience less late stage complications of advanced immunodeficiency. HIV itself, and longterm combination antiretroviral therapy (ART), increases the risks and complications associated with metabolic and non –communicable (NCD) diseases as people age. This guideline includes a new section on non-communicable diseases to guide the clinician to advise patients regarding the prevention of NCD, to incorporate screening for NCD into routine consultations, and for the investigation and management of NCD. The clinician is directed to Cambodian National NCD guidelines for management of hypertension and diabetes. Whilst the HIV clinician may not always lead the management of NCD if the patient has the opportunity to attend a specialised clinic, the HIV clinician must have a good understanding of these common conditions, and in particular drug interactions with ARV.